Daré Bioscience earnings date
Want to see DARE full AI Analyst Report?
Daré Bioscience (DARE) Q3 2026 Earnings Report
DARE Q3 2026 EPS Results
- Actual EPS
- -$0.18
- Consensus EPS
- -$0.13
- Beat/Miss
- Missed by -$0.05
- One Year Ago EPS
- -$0.28
DARE Q3 2026 Revenue Results
- Actual Revenue
- $47.63K
- Expected Revenue
- $2.04M
- Beat/Miss
- Missed by -$1.99M
- YoY Revenue Growth
- +2005.57%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/16/2026
- Time
- After Close
- Conference Call
- Monday, November 16, 2026
Daré Bioscience's next earnings date is estimated for April 1, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was strongly focused on commercial execution and portfolio expansion, with multiple product launches, broad early provider engagement, substantial nondilutive funding, clinical programs progressing toward 2027 data and potential applications for the DARE-IDDS platform. The principal negatives were that revenue remains very small, Flora Sync sales are still immaterial, DARE to PLAY dispensing initially covers only 28 states, SG&A increased and the company continues to report a net loss. Highlights significantly outweighed the lowlights.
The company expects prescription dispensing for DARE to PLAY Sildenafil Cream to begin in November, with dispensing planned to commence later this month in the 28 states where the outsourcing facility is currently licensed; it expects to advance licensing in the remaining states. Flora Sync LF5 is expected to become available on Amazon in early 2027, while Flora Renew and Flora Reset are both anticipated in early 2027, and DARE to RECLAIM availability through the 503B compounding pathway is targeted for 2027. Management is moving the Ovaprene and DARE-HPV clinical studies toward readouts on both programs in 2027 and is pursuing additional collaborations for DARE-IDDS applications in obesity, diabetes, hormone therapies and neurologic disease, including potential applications with GLP-1 medicines.
- Commercial Launches and Near-Term Product AvailabilityFlora Sync LF5 is in the market, with first product sales beginning in July. DARE to PLAY Sildenafil Cream is en route from the 503B outsourcing facility to Medvantx, with prescription dispensing expected to begin in November 2026.
- Flora Sync LF5 Early Commercial TractionAlthough first-month revenue was described as not material, Flora Sync LF5 orders have come from 27 states, the company has received its first provider-office reorder, and customers have reported purchasing after receiving a provider recommendation or sample. The product had a 4.9-star review rating after approximately 25 initial reviews.
- Flora Sync LF5 Expansion PlansFlora Sync LF5 is currently available through the DARE Health Hub and clinician offices. The company plans to make it available on Amazon in early 2027 and is evaluating additional online and brick-and-mortar retail channels. Flora Renew and Flora Reset are also anticipated in early 2027 and are expected to follow similar channels.
- DARE to PLAY Prescription and Provider EngagementBefore product availability, 182 office-based providers had written DARE to PLAY prescriptions. Including office-based providers and telehealth, prescriptions had been written across 48 states and the District of Columbia. The company also received its first direct office order during the sexual health conference held the prior weekend.
- DARE to PLAY Commercial-Scale ManufacturingThe company stated that DARE to PLAY is being produced at commercial scale by a registered 503B outsourcing facility operating under pharmaceutical good manufacturing practice requirements, rather than being compounded one tube at a time at a 503A pharmacy.
- DARE to PLAY Market Opportunity and Differentiated EvidenceThe company estimates that approximately 20 million women in the United States experience symptoms of low or no sexual arousal. At a price of $99 per tube, providing approximately 10 uses, the estimated addressable population represents a total market opportunity of approximately $2 billion. Daré said DARE to PLAY is differentiated by clinical evidence showing increased blood flow within 10 to 15 minutes of application and improvement in arousal response using clinically validated FDA-reviewed endpoints.
- Multiple DARE to PLAY Access ChannelsDARE to PLAY is available through the DARE Health Hub, including the company's asynchronous telehealth questionnaire, through prescriptions submitted by existing clinicians, through direct office purchase and dispensing, and through telehealth practices such as MyMenopauseRx. Daré is pursuing additional collaborations and other channels while seeking to protect pricing and avoid concentration risk.
- Dual-Path Regulatory and Commercial StrategyThe 503B pathway provides a way to make DARE to PLAY available by prescription while Daré continues engaging with the FDA on a Phase III development program and pursues potential approval through the 505(b)(2) regulatory pathway.
- Nondilutive Funding and Grant SupportAcross its portfolio, Daré has been awarded more than $60 million from the Gates Foundation, $10 million through ARPA-H and more than $5 million through NIH and NICHD-supported programs. In October, it received a $1.5 million installment for DARE-LARC1, bringing total funding under that agreement to approximately $43.3 million. It also received approximately $852,000 under its $10.7 million Gates Foundation grant, bringing total funding under that agreement to approximately $9.9 million.
- Clinical Pipeline ProgressDaré initiated the DARE-HPV Phase II study and expects data from DARE-HPV and the pivotal Phase III Ovaprene study in 2027. Ovaprene is an investigational hormone-free monthly intravaginal contraceptive, while DARE-HPV is being studied for persistent high-risk HPV infection.
- Patent and Scientific Evidence AdvancesThe company announced a new U.S. patent expected to provide protection into at least 2039. It also published new peer-reviewed Sildenafil Cream data in postmenopausal women and men, expanding the evidence base it is using for the product.
- DARE to RECLAIM OpportunityDARE to RECLAIM, an estradiol and progesterone intravaginal ring, is targeted for availability through the 503B compounding pathway in 2027. The company stated that it would currently be the only clinically studied product delivering both hormones in a once-a-month vaginal format.
- DARE-IDDS Platform Expansion PotentialThe DARE-IDDS programmable drug-delivery platform underlying DARE-LARC1 is designed to remotely control drug release over months to years. Daré is exploring strategic collaborations involving obesity, diabetes, hormone therapies and neurologic disease, including potential applications with GLP-1 medicines.
- Improved Quarterly Net Loss and Lower R&D ExpenseThird-quarter 2026 net loss was approximately $3.2 million, compared with approximately $3.6 million in the third quarter of 2025. Research and development expense was approximately $0.3 million, down from approximately $1.2 million in the prior-year period, with the company attributing the decrease primarily to lower spending across several development programs and the impact of nondilutive funding.
- National Focus on Women's HealthThe company cited a new executive order calling for a dedicated NIH Women's Health Division and a White House Women's Health Task Force, with goals including better coordination of research and federal action. Daré said continued national attention may create additional nondilutive funding and collaboration opportunities.
DARE Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Apr 01, 2027 | 2026 (Q4) | -0.19- | -0.2 | ― | ― |
| Nov 16, 2026 | 2026 (Q3) | -0.13-0.18 | -0.28 | 35.71% (+0.10) | |
| Aug 13, 2026 | 2026 (Q2) | -0.30-0.20 | -0.45 | 55.56% (+0.25) | |
| May 14, 2026 | 2026 (Q1) | -0.30-0.20 | -0.5 | 60.00% (+0.30) | |
| Mar 26, 2026 | 2025 (Q4) | -0.440.03 | -0.61 | 104.92% (+0.64) | |
| Nov 13, 2025 | 2025 (Q3) | -0.38-0.28 | -0.55 | 49.09% (+0.27) | |
| Aug 14, 2025 | 2025 (Q2) | -0.58-0.45 | 1.52 | -129.61% (-1.97) | |
| May 13, 2025 | 2025 (Q1) | ―-0.50 | -0.84 | 40.48% (+0.34) | |
| Mar 31, 2025 | 2024 (Q4) | -0.58-0.50 | -0.84 | 40.48% (+0.34) | |
| Nov 14, 2024 | 2024 (Q3) | -0.69-0.55 | -1.09 | 49.73% (+0.54) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

